388 related articles for article (PubMed ID: 25326839)
21. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Briones M; Bajaj M
Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
[TBL] [Abstract][Full Text] [Related]
22. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
[TBL] [Abstract][Full Text] [Related]
23. Glycemic Control in the Treatment of Psoriasis.
Ip W; Kirchhof MG
Dermatology; 2017; 233(1):23-29. PubMed ID: 28538228
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
[TBL] [Abstract][Full Text] [Related]
27. [Exenatide: use in humans].
Sierra-Ascencio ME; Ríos-Vaca A; Reza-Albarrán A
Gac Med Mex; 2006; 142(6):483-91. PubMed ID: 17201111
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
29. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
Lund A; Knop FK; Vilsbøll T
Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
[TBL] [Abstract][Full Text] [Related]
31. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
32. GLP-1 as a target for therapeutic intervention.
Rajeev SP; Wilding J
Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
[TBL] [Abstract][Full Text] [Related]
33. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Blumer I; Pettus JH; Santos Cavaiola T
Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
[TBL] [Abstract][Full Text] [Related]
35. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
36. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
[TBL] [Abstract][Full Text] [Related]
37. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
Hanefeld M; Raccah D; Monnier L
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
[TBL] [Abstract][Full Text] [Related]
38. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
Salvador J; Andrada P
Med Clin (Barc); 2014; 143 Suppl 2():28-34. PubMed ID: 25326841
[TBL] [Abstract][Full Text] [Related]
39. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
Boyle JG; Livingstone R; Petrie JR
Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]